What is Emboline?
Founded in 2011 and based in Santa Cruz, California, Emboline, Inc. is an emerging medical device firm specializing in embolic protection. Its flagship product, the Emboliner Embolic Protection Catheter, is designed to mitigate embolic risks in Transcatheter Aortic Valve Replacement (TAVR) and other interventional procedures. The Emboliner technology aims to enhance patient safety by reliably protecting the cerebral system and capturing non-cerebral debris, stemming from intellectual property developed by Amir Belson.
How much funding has Emboline raised?
Emboline has raised a total of $80M across 4 funding rounds:
Series B
$10M
Other Financing Round
$5M
Series C
$10M
Series D
$55M
Series B (2018): $10M with participation from ShangBay Capital and SV Tech Ventures
Other Financing Round (2020): $5M led by Undisclosed
Series C (2021): $10M, investors not publicly disclosed
Series D (2021): $55M featuring Matrix Capital Management, SV Tech, ShangBay Capital, and Global Assets Investment
Key Investors in Emboline
ShangBay Capital
ShangBay Capital is a venture capital firm established in 2015, specializing in medical devices, biotechnology, and healthcare, with a focus on seed and early-stage investments.
SV Tech Ventures
SV Tech Ventures is an investment entity that has participated in Emboline's funding rounds, contributing to the company's growth in the medical device sector.
Matrix Capital Management
Matrix Capital Management Company, headquartered in Waltham, Massachusetts, is an investment fund with a strategic focus on technology and life sciences.
What's next for Emboline?
The substantial capital infusion, particularly the recent major strategic investment, positions Emboline for accelerated growth and market penetration. This backing is indicative of a company likely in its scaling phase, poised to advance its product development, expand its commercial reach, and potentially pursue regulatory approvals. The strategic nature of the latest financing suggests a focus on strengthening market position and forging key partnerships within the interventional cardiology and cardiovascular device sectors.
See full Emboline company page
